Taysha Gene Therapies (NASDAQ:TSHA) just reported results for the first quarter of 2024.
- Taysha Gene Therapies reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -11 cents.
- The company reported revenue of $3.41 million.
- This was 33.24% better than the analyst estimate for revenue of $2.56 million.